FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Aurobindo Pharma Rasagiline Tablets 0 Recall

Rasagiline Tablets 0

Aurobindo Pharma USA Inc. · East Windsor, NJ

Risk level
Class II
Reported by FDA
Sep 27, 2023
Recall ID
D-1171-2023
Check your lot numberHow we source this data

Summary

Aurobindo Pharma recalled Rasagiline Tablets 0 starting Aug 2, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1171-2023 on Sep 27, 2023. Reason: Failed dissolution specifications - results obtained were below spec average. Status: Terminated.

Why it was recalled

Failed dissolution specifications - results obtained were below spec average.

Product description

Rasagiline Tablets 0.5mg, 30-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A., NDC 0378-1270-93

Lot numbers, UPCs & expiration codes

Lot #: 3112444, Exp 8/2023

Where it was sold

USA nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1171-2023
Classification
Class II
Status
Terminated
Recall initiated
Aug 2, 2023
FDA report date
Sep 27, 2023
Quantity
9,890 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Aurobindo Pharma USA Inc.

Original FDA data

Every field from FDA enforcement report D-1171-2023, exactly as published.

Show all FDA fields
City
East Windsor
State
NJ
Status
Terminated
Country
United States
Event ID
92948
Address
279 Princeton Hightstown Rd
Code information
Lot #: 3112444, Exp 8/2023
Postal code
08520-1401
Report date
Sep 27, 2023
Product type
Drugs
Recall number
D-1171-2023
Classification
Class II
Recalling firm
Aurobindo Pharma USA Inc.
Product quantity
9,890 bottles
Termination date
Aug 19, 2024
Reason for recall
Failed dissolution specifications - results obtained were below spec average.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Rasagiline Tablets 0.5mg, 30-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A., NDC 0378-1270-93
Distribution pattern
USA nationwide
Recall initiation date
Aug 2, 2023
Initial firm notification
Letter
Center classification date
Sep 18, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1171-2023, published Sep 27, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls